UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 13,618 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 1.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 906,304 shares of the company's stock after acquiring an additional 13,618 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.73% of Henry Schein worth $62,716,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC lifted its stake in shares of Henry Schein by 3,347.1% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the company's stock valued at $41,000 after buying an additional 569 shares in the last quarter. Quent Capital LLC lifted its stake in shares of Henry Schein by 91.2% during the 4th quarter. Quent Capital LLC now owns 677 shares of the company's stock valued at $47,000 after buying an additional 323 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Henry Schein by 23.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock valued at $52,000 after buying an additional 143 shares in the last quarter. Allworth Financial LP lifted its stake in shares of Henry Schein by 180.7% during the 4th quarter. Allworth Financial LP now owns 946 shares of the company's stock valued at $71,000 after buying an additional 609 shares in the last quarter. Finally, Canada Post Corp Registered Pension Plan purchased a new stake in shares of Henry Schein during the 4th quarter valued at approximately $95,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Piper Sandler lowered their target price on shares of Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. Wells Fargo & Company lowered their target price on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. UBS Group lowered their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 26th. Barrington Research lowered their target price on shares of Henry Schein from $90.00 to $86.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Finally, Wall Street Zen cut shares of Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $79.30.

Insiders Place Their Bets

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the firm's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares of the company's stock, valued at $4,460,251.20. This trade represents a 6.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now directly owns 24,805 shares in the company, valued at approximately $1,762,147.20. This trade represents a 9.50% decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Henry Schein Price Performance

Shares of NASDAQ:HSIC traded down $1.97 during trading on Friday, reaching $70.01. The company had a trading volume of 917,312 shares, compared to its average volume of 1,664,339. The company has a fifty day moving average of $67.64 and a two-hundred day moving average of $71.61. The stock has a market capitalization of $8.52 billion, a P/E ratio of 28.82, a price-to-earnings-growth ratio of 2.13 and a beta of 0.87. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.11 by $0.04. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. During the same quarter in the prior year, the firm earned $1.10 EPS. The business's revenue for the quarter was down .1% compared to the same quarter last year. Equities research analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.